# B-cell Acute Lymphoblastic Leukemia in a Patient With Crohn’s Disease After Anti-TNF-Alpha Treatment

## TL;DR

A patient with Crohn's disease developed leukemia 16 years after diagnosis, highlighting the need for cancer surveillance in those on immunosuppressive therapy.

## Contribution

This case report adds to the understanding of cancer risks in Crohn's disease patients undergoing long-term immunosuppressive treatments.

## Key findings

- A patient with Crohn's disease developed B-cell acute lymphoblastic leukemia 16 years after diagnosis.
- Immunosuppressive therapies used included azathioprine, infliximab, vedolizumab, steroids, and hyper-CVAD chemotherapy.
- The case underscores the increased cancer risk in Crohn's disease patients on immunosuppressive therapy.

## Abstract

This case report details a patient with Crohn's disease (CD) who developed acute lymphoblastic leukemia (ALL) 16 years after their initial diagnosis. Various immunosuppressive therapies used in the treatment included azathioprine, infliximab and, for a short period, vedolizumab and steroids for CD and hyper-CVAD chemotherapy for leukemia. The association between CD and increased cancer risk, particularly hematological malignancies, emphasizes the importance of regular cancer surveillance, including hematological assessments, for patients on immunosuppressive therapy.